Simris Group AB (PUBL) (STO:SIMRIS.B)
0.1425
-0.0295 (-17.15%)
At close: Feb 10, 2026
Simris Group AB (PUBL) Revenue
Simris Group AB (PUBL) had revenue of 484.00K SEK in the quarter ending September 30, 2025, a decrease of -36.81%. This brings the company's revenue in the last twelve months to 2.30M, down -49.72% year-over-year. In the year 2024, Simris Group AB (PUBL) had annual revenue of 2.89M, down -33.62%.
Revenue (ttm)
2.30M
Revenue Growth
-49.72%
P/S Ratio
72.59
Revenue / Employee
383.50K
Employees
6
Market Cap
167.02M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 2.89M | -1.46M | -33.62% |
| Dec 31, 2023 | 4.35M | 274.00K | 6.72% |
| Dec 31, 2022 | 4.08M | -2.29M | -35.92% |
| Dec 31, 2021 | 6.37M | 4.08M | 178.77% |
| Dec 31, 2020 | 2.28M | 541.00K | 31.04% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Magle Chemoswed Holding AB | 300.49M |
| Xbrane Biopharma AB | 259.70M |
| IRLAB Therapeutics AB | 85.56M |
| Sprint Bioscience AB | 50.03M |
| Elicera Therapeutics AB | 13.70M |
| NextCell Pharma AB | 11.06M |
| Biovica International AB | 9.89M |
| Xintela AB | 2.96M |